AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.